Therapy Areas: AIDS & HIV
Adamis Pharmaceuticals Announces FDA Acceptance for Review of the New Drug Application of Its Higher Dose Naloxone Injection Product Candidate
18 March 2019 - - The US Food and Drug Administration has accepted for review the company's New Drug Application for its higher naloxone injection product candidate for the treatme...
AbCellera Signs Agreement with Global Health Foundation to Fight Infectious Disease
15 March 2019 - - Canada-based therapeutic antibodies developer AbCellera has inked a two-year agreement with the Bill and Melinda Gates Foundation to help accelerate global health research, the ...
Shield Diagnostics unveils Target-NG test for antibiotic susceptibility in Neisseria gonorrhoeae
14 March 2019 - Andreessen Horowitz-backed clinical laboratory Shield Diagnostics revealed on Wednesday the availability of the rapid molecular test Target-NG for antibiotic susceptibility in Neisseri...
First Patient Dosed in Phase 1 Clinical Trial of Rocket Pharmaceuticals' RP-L102 in the US
13 March 2019 - - The first patient has been dosed in the open-label, Phase 1 clinical trial of RP-L102, US-based multi-platform gene therapy company Rocket Pharmaceuticals, Inc.'s (NASDAQ: ...
Gilead Sciences reveals findings from two GS-6207 studies
11 March 2019 - United States-based Gilead Sciences has revealed findings from two studies that support the further development of GS-6207, a novel, selective, first-in-class inhibitor of HIV-1 capsid...
Gilead Releases Data Showing Non-Inferiority of Once-Daily Descovy vs. Once-Daily Truvada for Prevention of HIV Infection
8 March 2019 - - US-based biopharmaceutical company Gilead Sciences, Inc. (NASDAQ: GILD) has received results from the DISCOVER trial, a two-year Phase 3 randomized, controlled, double-blind study eva...